NCT05345093View on ClinicalTrials.gov

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Acne VulgarisFolliculitis
Interventions
DEVICE

Ialuxid gel

"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."

Trial Locations (1)

450117

SC Salvosan Ciobanca SRL, Zalău

Sponsors

Lead Sponsor

BMG Pharma
All Listed Sponsors
collaborator

Opera CRO, a TIGERMED Group Company

OTHER

lead

BMG Pharma

INDUSTRY

NCT05345093 - Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis | Biotech Hunter | Biotech Hunter